The B7-H3 (Enoblituzumab) Biosimilar Antibody (MAB-HDBS0010) is a monoclonal antibody developed for research purposes targeting the B7-H3 protein, a cell surface molecule that plays a vital role in immune regulation and tumor immunity. This biosimilar antibody, derived from Enoblituzumab, binds specifically to the B7-H3 protein, allowing for accurate detection and characterization in various cell types.The B7-H3 protein has been identified as a promising target for cancer immunotherapy due to its role in immune checkpoint regulation and tumor progression.
By targeting B7-H3, researchers can further investigate its function in cancer development and explore potential therapeutic strategies for cancer treatment.This high-quality biosimilar antibody is suitable for a wide range of research applications, including Western blotting, immunohistochemistry, and flow cytometry. Its specificity and sensitivity make it a valuable tool for studying the biological functions of B7-H3 and its potential as a therapeutic target in cancer research.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
MG-A271, MGA271
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
